This segment focuses on the research, development, and clinical trials of therapeutics for Alzheimer's disease. The primary focus is on atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor. Research and development activities include preclinical studies, Phase II/III clinical trials, and analysis of clinical data to assess efficacy and safety. The company utilizes advanced methodologies in drug discovery and development, including understanding the role of P. gingivalis in Alzheimer's pathology. The patient impact is aimed at slowing or halting the progression of Alzheimer's disease, improving cognitive function, and enhancing the quality of life for patients. Market positioning is based on a novel approach to treating Alzheimer's, targeting the underlying cause of the disease. Future opportunities include expanding the therapeutic applications of atuzaginstat and developing new drug candidates. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial guidelines. Partnerships and collaborations are essential for clinical trial execution and drug development.

This segment encompasses the development of gingipain inhibitors, such as atuzaginstat, for various degenerative diseases beyond Alzheimer's. Research and development efforts include exploring the potential of gingipain inhibition in treating oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company utilizes advanced drug discovery platforms and clinical trial methodologies to evaluate the efficacy and safety of gingipain inhibitors in different disease indications. The therapeutic areas covered include oncology, dentistry, and infectious diseases. The patient impact aims to provide new treatment options for diseases where gingipains play a significant role in disease progression. Market positioning is based on targeting a novel mechanism of action with the potential to address multiple diseases. Future opportunities include expanding the clinical trial pipeline and exploring new therapeutic applications. Regulatory and clinical aspects involve obtaining necessary approvals for each indication. Partnerships and collaborations are crucial for conducting clinical trials and commercializing the products.